Lilly Receives Emergency Use Approval for Omicron Treatment
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has received Emergency Use Authorization for its investigational drug bebtelovimab, an antibody therapy to treat the COVID Omicron variant. The EUA comes as the company announces a $720 million deal with the U.S. government to supply up to 600,000 doses.
Lilly says bebtelovimab is used for the treatment of mild to moderate COVID-19 in certain high-risk patients and has proven successful in clinical trials.
“With the emergence of variants such as Omicron, treatment options remain limited,” said Dr. Daniel Skovronsky, Lilly’s chief scientific and medical officer. “Lilly is pleased to provide another treatment option to help address the ongoing needs of patients and health care providers who continue to battle this pandemic.”
The supply agreement with the U.S. government calls for the delivery of up to 600,000 doses no later than March 31 with an option of 500,000 additional doses no later than July 31.